The role of fractalkine in the development of diabetic macular edema in patients with type 2 diabetes mellitus
Background. Diabetic macular edema (DME) is a severe complication of type 2 diabetes mellitus (DM) and a leading cause of vision loss in the working age population of most developed countries. The gold standard for DME treatment should be based on a good control of glycemia along with control of lip...
Main Authors: | M.L. Kyryliuk, S.А. Suk, S.O. Rykov, S.Yu. Mogilevskyy |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaslavsky O.Yu.
2019-02-01
|
Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
Subjects: | |
Online Access: | http://iej.zaslavsky.com.ua/article/view/158686 |
Similar Items
-
Predicting the risk of diabetic retinopathy-associated macular edema in patients with type 2 diabetes mellitus
by: S.Yu. Mogilevskyy, et al.
Published: (2019-06-01) -
Pathogenesis of diabetic macular edema: the role of pro-inflammatory and vascular factors. A literature review
by: M.L. Kyryliuk, et al.
Published: (2022-05-01) -
Pathogenesis of diabetic macular edema: role of the glial factor (literature review and own data)
by: M.L. Kyryliuk, et al.
Published: (2023-10-01) -
Blood sICAM-1 levels in type 2 diabetes mellitus patients with various grades of DME
by: S.A. Suk, et al.
Published: (2019-10-01) -
Analysis on related factors of diabetic macular edema
by: Xiao-Chuan Wang, et al.
Published: (2013-08-01)